Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: A case report

1 May 2023

Abstract excerpt

Unprecedented immunization campaigns have been rolled out worldwide in an attempt to contain the ongoing COVID-19 pandemic. Multiple vaccines were brought to the market, among two utilizing novel messenger ribonucleic acid technology. Despite their undisputed success in decreasing COVID-19-associated hospitalizations and mortality, various adverse events have been reported. The emergence of malignant lymphoma is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37197431
DOI: 10.3389/fonc.2023.1158124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: A case reportPMID 37197431Read ↗

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patientsSemantic proximity Read ↗

Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responsesSemantic proximity Read ↗

A Case Report of Acute Lymphoblastic Leukaemia (ALL)/Lymphoblastic Lymphoma (LBL) Following the Second Dose of Comirnaty®: An Analysis of the Potential Pathogenic Mechanism Based on of the Existing LiteratureSemantic proximity Read ↗

Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engagerSemantic proximity Read ↗

Case Report of COVID-19 Vaccination in a Rituximab-treated Mantle Cell Lymphoma PatientSemantic proximity Read ↗

COVID ‐19 mRNA vaccine‐related interstitial lung disease: Two case reports and literature reviewSemantic proximity Read ↗

Cutaneous Reactions after COVID-19 Vaccines – Analysis of the Clinical and Histological Spectrum – Case Series and Review of the LiteratureSemantic proximity Read ↗

Cytokine Release Syndrome–Compatible Fever After Initiation of Local Radiotherapy During Late-Phase Epcoritamab Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case ReportSemantic proximity Read ↗

Cutaneous lymphocytic vasculitis after administration of COVID ‐19 mRNA vaccineSemantic proximity Read ↗

Pilot study of p62 DNA vaccine in dogs with mammary tumorsSemantic proximity Read ↗

Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivoSemantic proximity Read ↗

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well-tolerated and efficacious in rodent modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.